Menu
- I See Blood Cancer
- Patient discussions
Menu
Waldenström’s macroglobulinemia
I See Waldenström's macroglobulinemia (WM)
I See Waldenström's macroglobulinemia (WM)
Welcome to I see Waldenström’s macroglobulinemia, a dedicated resource to help healthcare practitioners find the latest information about the signs, symptoms and diagnosis of WM.
What is Waldenström's macroglobulinemia (WM)?
Waldenström’s macroglobulinemia (WM) is a chronic, indolent, B-cell disorder characterised by bone marrow infiltration with lymphoplasmacytic cells, along with IgM monoclonal gammopathy.[1][2]
What are the causes and the main symptoms of WM?
A quick overview of the mutation that leads to the development of WM, what are the disease manifestations, and the relevance of the asymptomatic disease.
CP-299789, approved on 11/05/2022
WM statistics
of Non-Hodgkin lymphomas[3]
Median age of diagnosis[3]
~2x more common in men[3]
Median overall survival[4]
WM incidence rates
In Europe, the WM incidence rate is 7.3 per million in men, and 4.2 per million in women[3]
A strong familial predisposition has been reported,[3][5] first-degree relatives of WM patients have up to 20-fold increased risk for developing WM (and also increased risk but at lower level for other B-cell disorders).[3]
In contrast to multiple myeloma, WM prevalence is higher among Caucasians than other races.[3][6]
Epidemiological data and risk evaluation in WM
Have a look at the International Prognostic Scoring System for Waldenström's Macroglobulinemia (IPSSWM) to evaluate the probability of progression, and its correlation with median survival.
CP-299791, approved on 11/05/2022
Risk factors
The main risk factor for WM is the presence of IgM-monoclonal gammopathy of uncertain significance (MGUS).[7][8] Whilst in most people, MGUS remains stable and doesn’t cause problems or need treatment, there is a risk of MGUS developing into a cancer.[9] The presence of IgM-MGUS increases the risk of WM by 46 times vs. the general population.[10][11]
Other risk factors include:[10][11]:
Genetic predisposition[3][7]
Presence of autoimmune disease[7]
History of infections[7]
WM immunophenotype and genetic mutations
WM cells are characterised by very specific immunophenotypes[3][^7]:
Positive for WM
IgM, CD19, CD20, CD22, CD25, CD27, CD79a
Variable for WM
CD5, CD10, CD23, CD138
Negative for WM
CD103
These characteristic immunophenotypes differentiate WM from other Non-Hodgkin lymphomas and from multiple myeloma (MM).[7]
Patients with WM present with different genetic variations, with the most common being del (6q) together with the somatic mutation in MYD88(L265P).[7] The latter has an important role in the growth and survival of WM cells.[1][7]
Learn about the steps involved in diagnosing your patient’s WM
Learn about the steps involved in diagnosing your patient’s WM
Other blood cancer conditions
I see AL amyloidosis
The latest insights into diagnosing and treating AL amyloidosis.
I see mantle cell lymphoma (MCL)
Current advice regarding the diagnosis and treatment of MCL.
I see acute myeloid leukaemia (AML)
Most recent guidance into diagnosing and treating acute myeloid leukaemia.
A dedicated online resource for healthcare professionals to learn about the diagnosis and management of rare haematological malignancies: AL amyloidosis, Waldenström's macroglobulinemia, mantle cell lymphoma and acute myeloid leukaemia.
Download this information on Waldenström's
macroglobulinemia
CD=cluster of differentiation; IgM=immunoglobulin M; MGUS=monoclonal gammopathy of uncertain significance; WM=Waldenström’s macroglobulinemia.
This site has been developed by Janssen-Cilag International NV. Janssen-Cilag International NV is the responsible editor of this document.
CP-343204 - September 2022
